Stock Scorecard
Stock Summary for Rigel Pharmaceuticals (RIGL) - $24.31 as of 11/20/2024 8:38:57 PM EST
Total Score
9 out of 30
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for RIGL
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for RIGL
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for RIGL
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 | |
Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for RIGL
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Safety Rating Criteria for RIGL (34 out of 90)
Stock Price Rating (Max of 10) | 7 |
Historical Stock Price Rating (Max of 10) | 8 |
Stock Price Trend (Max of 10) | 2 |
Book Value (Max of 10) | 1 |
Book Value to Price (Max of 10) | 0 |
Analyst Buy Ratings (Max of 5) | 2 |
Analyst Strong Buy Ratings (Max of 5) | 3 |
Dividend Yield Percentage (Max of 10) | 0 |
Operating Margin (Max of 10) | 5 |
Trading Volume (Max of 10) | 4 |
Price to Earnings (Max of 10) | 2 |
Latest News for for RIGL
Financial Details for RIGL
Company Overview |
|
---|---|
Ticker | RIGL |
Company Name | Rigel Pharmaceuticals |
Country | USA |
Description | Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is headquartered in South San Francisco, California. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 9/30/2024 |
Next Earnings Date | N/A |
Stock Price History |
|
Last Day Price | 24.31 |
Price 4 Years Ago | 35.00 |
Last Day Price Updated | 11/20/2024 8:38:57 PM EST |
Last Day Volume | 168,437 |
Average Daily Volume | 216,788 |
52-Week High | 29.82 |
52-Week Low | 7.48 |
Last Price to 52 Week Low | 225.00% |
Valuation Measures |
|
Trailing PE | 84.22 |
Industry PE | 22.60 |
Sector PE | 40.32 |
5-Year Average PE | -115.16 |
Free Cash Flow Ratio | 7.01 |
Industry Free Cash Flow Ratio | 12.03 |
Sector Free Cash Flow Ratio | 27.97 |
Current Ratio Most Recent Quarter | 1.96 |
Total Cash Per Share | 3.47 |
Book Value Per Share Most Recent Quarter | -0.83 |
Price to Book Ratio | 31.64 |
Industry Price to Book Ratio | 5.31 |
Sector Price to Book Ratio | 20.88 |
Price to Sales Ratio Twelve Trailing Months | 2.55 |
Industry Price to Sales Ratio Twelve Trailing Months | 11.82 |
Sector Price to Sales Ratio Twelve Trailing Months | 7.11 |
Analyst Buy Ratings | 1 |
Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
Total Shares Outstanding | 17,615,000 |
Market Capitalization | 428,220,650 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Total Years Dividend Increasing | N/A |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 1.33% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | -47.90% |
Annual Earnings Growth | 57.16% |
Reported EPS 12 Trailing Months | 0.27 |
Reported EPS Past Year | 0.59 |
Reported EPS Prior Year | -0.15 |
Net Income Twelve Trailing Months | 3,881,000 |
Net Income Past Year | -25,091,000 |
Net Income Prior Year | -58,573,000 |
Quarterly Revenue Growth YOY | 96.60% |
5-Year Revenue Growth | 19.93% |
Operating Margin Twelve Trailing Months | 0.25 |
Balance Sheet |
|
Total Cash Most Recent Quarter | 61,114,000 |
Total Cash Past Year | 56,933,000 |
Total Cash Prior Year | 58,206,000 |
Net Cash Position Most Recent Quarter | 1,114,000 |
Net Cash Position Past Year | -3,067,000 |
Long Term Debt Past Year | 60,000,000 |
Long Term Debt Prior Year | 40,000,000 |
Total Debt Most Recent Quarter | 60,000,000 |
Equity to Debt Ratio Past Year | -0.91 |
Equity to Debt Ratio Most Recent Quarter | -0.32 |
Total Stockholder Equity Past Year | -28,644,000 |
Total Stockholder Equity Prior Year | -13,616,000 |
Total Stockholder Equity Most Recent Quarter | -14,636,000 |
Free Cash Flow |
|
Free Cash Flow Twelve Trailing Months | 10,368,000 |
Free Cash Flow Per Share Twelve Trailing Months | 0.59 |
Free Cash Flow Past Year | -20,743,000 |
Free Cash Flow Prior Year | -74,208,000 |
Options |
|
Put/Call Ratio | 1.00 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 2.60 |
MACD Signal | 1.08 |
20-Day Bollinger Lower Band | 5.13 |
20-Day Bollinger Middle Band | 13.89 |
20-Day Bollinger Upper Band | 22.65 |
Beta | 0.95 |
RSI | 91.58 |
50-Day SMA | 12.53 |
150-Day SMA | 14.43 |
200-Day SMA | 20.10 |
System |
|
Modified | 11/19/2024 11:32:35 AM EST |